Table 3.
Positive haemodynamic response to vasoreactivity testing
| Levosimendan | NO | Iloprost | |
| mPAP <40 mmHg/decrease ≥10 mmHg with increased/unchanged CI | 10 (71) | 9 (64) | 1 (14)* |
| PVR < 2.5 WU with systolic BP ≥ 85 mmHg | 1 (7) | 6 (43) | 1 (14) |
| PASP < 50 mmHg with either TPG < 15 mmHg or PVR ≤ 3WU | 5 (36) | 6 (43) | 0* |
| Institution's criteria | |||
| TPG drop ≥25% | 7 (50) | 12 (86) | 3 (43) |
| CI increase ≥40% | 8 (57)* | 0 | 2 (29) |
| PAWP decrease | 9 (64) | 3 (21) | 3 (43) |
| Two out of 3 criteria | 9 (64)* | 2 (14) | 1 (14) |
| Fully responsive | 2 (14) | 0 | 0 |
Qualitative assessment of reversibility of pulmonary hypertension using various criteria in patients that underwent levosimendan (Lev, n = 14), NO (n = 14), and iloprost (Ilo, n = 7). The criteria are presented in the following order: Sitbon's criteria used to establish responsiveness to calcium‐channel blockers in idiopathic pulmonary artery hypertension, 10 Costard‐Jackle's 1992 heart transplanted patient cohort derived criteria, 11 reversion to no indication for vasoreactivity testing according to the International Society for Heart and Lung Transplantation criteria, 4 and finally, our own centre's protocol (please refer to the main manuscript). BP, blood pressure; CI, cardiac index; mPAP, mean pulmonary artery pressure; PASP, pulmonary artery systolic pressure; PAWP, pulmonary artery wedge pressure; PVR, pulmonary vascular resistance; TPG, transpulmonary gradient; WU, Wood units. Values are count (percentage).
P < 0.05 vs. other groups by z‐test for proportions (Bonferroni corrected) when significant differences were found on Fisher's test.